Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
PRIORITY PRESS - ASH 2023: Annual Meeting of the American Society of Hematology
“PNH is getting very popular!”: New clinical trial data and management insights from ASH 2023
San Diego, California / December 9–12, 2023
San Diego – Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired disorder of hematopoietic stem cells that leaves red blood cells (RBCs) susceptible to complement-mediated lysis, with clinical manifestations that can...
PRIORITY PRESS - SNO 2023: Annual Meeting of the Society for NeuroOncology
A deep dive into neurofibromatosis type 1: Expert experiences and perspectives from SNO 2023
Vancouver, British Columbia / November 15–19, 2023
Vancouver – The Society for NeuroOncology (SNO) is an international organization that brings together clinicians and researchers with an interest in central nervous system malignancies. Although a large part of its focus is on...
PRIORITY PRESS - SIOP 2023: Annual Meeting of the International Society of Paediatric Oncology
Understanding the burden and management of NF1: Insights from SIOP 2023
Ottawa, Ontario / October 11–14, 2023
Ottawa – The annual conference of the International Society of Paediatric Oncology (Société internationale d’oncologie pédiatrique, SIOP) brought clinicians and researchers from around the world to...
MEDICAL FRONTIERS - 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO)
A New Era Emerges In Melanoma Control, Including Brain Metastases
Chicago, Illinois / June 2-6, 2017
Chicago - A growing proportion of patients with advanced metastatic melanoma are surviving for long periods due largely to two approaches. One involves combining therapies targeted at the BRAF and MEK pathways. The other involves...
PRIORITY PRESS - Lung Cancer Summit 2015
The Right Drug at the Right Time in the Right Patient: Reflex Biomarker Testing in NSCLC Should Become a National Strategy
Toronto, Ontario / October 30, 2015
Toronto - Recent guidelines from the American Society of Clinical Oncologists state that systemic therapy for advanced non-squamous non-small cell lung cancer (NSCLC) should start with knowledge of a patient’s biomarker status...
PHYSICIAN PERSPECTIVE - Viewpoint based on presentations from the European Cancer Congress (ECC)
Neuroendocrine Tumours: Revised Strategies from New Trial Data
Vienna, Austria / September 25-29, 2015
Guest Editor: Simron Singh, MD, MPHStaff Oncologist Assistant Professor, University of TorontoSunnybrook Health Sciences Centre Toronto, Ontario Introduction NET is a term for a genetically diverse group of solid tumours arising...
PRIORITY PRESS - 39th Annual Congress of the European Society for Medical Oncology (ESMO)
Survival Data Justify Early Use of Androgen Pathway Inhibitor in Metastatic Castration Resistant Prostate Cancer
Madrid, Spain / September 26-30, 2014
Madrid - The final overall survival (OS) results of a phase 3 multicentre trial have confirmed the value of first-line androgen inhibition in metastatic castration resistant prostate cancer (mCRPC). In the study, early use of an androgen...
PRIORITY PRESS - 39th Congress of the European Society for Medical Oncology (ESMO)
Objective Response to a TKI in Metastatic Renal Cell Cancer Is Substantially Improved with Individualized Dose Schedules
Madrid, Spain / September 26-30, 2014
Madrid - Optimal response to a tyrosine kinase inhibitor (TKI) employed first line in metastatic renal cell carcinoma (mRCC) appears to be achieved by individualizing the dose and schedule in order to sustain dose intensity, according to...
PRIORITY PRESS - 39th Congress of the European Society for Medical Oncology (ESMO)
Targeted Therapies Moving into First-Line Therapy Underscore Need for Baseline Molecular Testing of Lung Cancers
Madrid, Spain / September 26-30, 2014
Madrid - Guidelines issued by ESMO just prior to the annual Congress call for routine molecular testing at the time of diagnosis in all patients with non-small cell lung cancer (NSCLC). New phase 3 data on ALK-positive (ALK+) NSCLC...